person · Reporting owner

Sohn Catherine A.

Disclosed activity across 6 companies

Tapewire entity: 50273
SEC CIK: 0001555132

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Altimmune, Inc.ALT · Entity 5349	Director	May 01, 2026	May 01, 2026
Axcella Health Inc.AXLA · Entity 116059	Director	May 19, 2022	May 23, 2022
Jazz Pharmaceuticals plcJAZZ · Entity 818	Director	August 11, 2023	August 15, 2023
LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447	Director	June 04, 2022	June 07, 2022
Maze Therapeutics, Inc.MAZE · Entity 1775	Director	January 06, 2026	January 08, 2026
Rubius Therapeutics, Inc.RUBY · Entity 116417	Director	May 12, 2022	May 13, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Altimmune, Inc.

Report date May 01, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2036-05-01	Direct	48,800	Reported balance After 2026-05-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-01 · Grant · Acquired 48,800 · Balance 48,800 F1: The options were granted pursuant to the Company's non-employee director compensation policy. F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options were granted pursuant to the Company's non-employee director compensation policy.

F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

Axcella Health Inc.

Report date May 19, 2022 · Filed May 23, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2032-05-18	Direct	20,000	Reported balance After 2022-05-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-19 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.

Jazz Pharmaceuticals plc

Report date August 11, 2023 · Filed August 15, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	14,868	Ending reported balance After 2023-08-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-08-11 · Grant · Acquired 3,075 · Balance 16,109 F1: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Row 2 · 2023-08-14 · Sale · Disposed 1,241 · Balance 14,868 F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.78 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Filing footnotes · ownership attribution and instrument terms

F1: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024.

F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.78 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

LIFECORE BIOMEDICAL, INC. \DE\

Report date June 04, 2022 · Filed June 07, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	54,069	Reported balance After 2022-06-04 transaction · row 1 1 source row Row 1 · 2022-06-04 · Grant · Acquired 7,059 · Balance 54,069 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2022-06-04	Direct	0	Reported balance After 2022-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-04 · Exercise / conversion · Disposed 7,059 · Balance 0 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: The restricted stock units were granted on June 4, 2021. F3: The restricted stock units vested on June 4, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2: The restricted stock units were granted on June 4, 2021.

F3: The restricted stock units vested on June 4, 2022.

Maze Therapeutics, Inc.

Report date January 06, 2026 · Filed January 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-01-07 transaction · row 6 6 source rows · reconciled sequence Row 1 · 2026-01-06 · Exercise / conversion · Acquired 2,493 · Balance 2,493 Row 2 · 2026-01-06 · Sale · Disposed 2,493 · Balance 0 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4. Row 3 · 2026-01-07 · Exercise / conversion · Acquired 20,744 · Balance 20,744 Row 4 · 2026-01-07 · Exercise / conversion · Acquired 2,895 · Balance 23,639 Row 5 · 2026-01-07 · Exercise / conversion · Acquired 3,281 · Balance 26,920 Row 6 · 2026-01-07 · Sale · Disposed 26,920 · Balance 0 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2033-03-08	Direct	3,211	Reported balance After 2026-01-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-06 · Exercise / conversion · Disposed 2,493 · Balance 3,211 F3: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2031-02-01	Direct	0	Reported balance After 2026-01-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-07 · Exercise / conversion · Disposed 20,744 · Balance 0 F4: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2033-03-08	Direct	316	Reported balance After 2026-01-07 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-01-07 · Exercise / conversion · Disposed 2,895 · Balance 316 F3: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2034-12-08	Direct	5,805	Reported balance After 2026-01-07 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-01-07 · Exercise / conversion · Disposed 3,281 · Balance 5,805 F5: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive.

F3: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

F4: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024.

F5: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Rubius Therapeutics, Inc.

Report date May 12, 2022 · Filed May 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11	Direct	25,000	Reported balance After 2022-05-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 01, 2026 Filed May 1, 2026 20:20 UTC	Altimmune, Inc. ALT · Entity 5349	GrantStock Options (option to buy) · Derivative	48,800	$0.00 Strike: $2.82	$0.00	Disclosure SEC source: 0001555132-26-000008 · form4-05012026_080545.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2036-05-01 F1 · security: The options were granted pursuant to the Company's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
January 07, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionStock Option (Right to Buy) · Derivative	3,281	$0.00 Strike: $10.42	$0.00	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · derivative · entry 10 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,805 Underlying: Common Stock · 3,281 shares Expires 2034-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document
January 07, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionStock Option (Right to Buy) · Derivative	2,895	$0.00 Strike: $10.42	$0.00	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · derivative · entry 9 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316 Underlying: Common Stock · 2,895 shares Expires 2033-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document
January 07, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionStock Option (Right to Buy) · Derivative	20,744	$0.00 Strike: $10.42	$0.00	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · derivative · entry 8 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,744 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024. Read SEC document
January 07, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	SaleCommon Stock	26,920	$39.11	$1,052,784.67	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · nonDerivative · entry 6 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive. Read SEC document
January 07, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionCommon Stock	3,281	$10.42	$34,188.02	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · nonDerivative · entry 5 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 07, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionCommon Stock	2,895	$10.42	$30,165.90	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · nonDerivative · entry 4 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 07, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionCommon Stock	20,744	$10.42	$216,152.48	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · nonDerivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionStock Option (Right to Buy) · Derivative	2,493	$0.00 Strike: $10.42	$0.00	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · derivative · entry 7 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,211 Underlying: Common Stock · 2,493 shares Expires 2033-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	SaleCommon Stock	2,493	$38.62	$96,269.69	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4. Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:30 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	Exercise / conversionCommon Stock	2,493	$10.42	$25,977.06	Disclosure SEC source: 0001555132-26-000006 · form4-01082026_090134.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 05, 2026 Filed Jan 5, 2026 21:05 UTC	Altimmune, Inc. ALT · Entity 5349	PurchaseCommon Stock, par value $0.0001	500	$4.24	$2,117.55	Disclosure SEC source: 0001555132-26-000002 · form4-01052026_040104.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Read SEC document
September 25, 2025 Filed Sep 29, 2025 20:21 UTC	Altimmune, Inc. ALT · Entity 5349	GrantStock Options (option to buy) · Derivative	48,800	$0.00 Strike: $3.92	$0.00	Disclosure SEC source: 0001104659-25-094503 · tm2527377-9_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2035-09-25 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
September 22, 2025 Filed Sep 24, 2025 20:19 UTC	Maze Therapeutics, Inc. MAZE · Entity 1775	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $23.67	$0.00	Disclosure SEC source: 0001555132-25-000005 · form4-09242025_080925.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-09-21 F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document
March 17, 2025 Filed Mar 18, 2025 20:15 UTC	Altimmune, Inc. ALT · Entity 5349	PurchaseCommon Stock, par value $0.0001	1,000	$5.78	$5,784.50	Disclosure SEC source: 0001104659-25-025032 · tm259651-1_4seq1.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document
February 06, 2025 Filed Feb 7, 2025 21:05 UTC	Altimmune, Inc. ALT · Entity 5349	GrantStock Options (option to buy) · Derivative	18,600	$0.00 Strike: $6.91	$0.00	Disclosure SEC source: 0001104659-25-010528 · tm255923-1_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock, par value $0.0001 · 18,600 shares Expires 2035-02-06 F1 · derivative.exercise_date: The shares underlying the option shall vest as follows: (i) 50% on July 15, 2025, (ii) 25% on September 30, 2025 and 25% on December 31, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
September 26, 2024 Filed Sep 30, 2024 22:33 UTC	Altimmune, Inc. ALT · Entity 5349	GrantStock Options (option to buy) · Derivative	34,900	$0.00 Strike: $6.81	$0.00	Disclosure SEC source: 0001104659-24-104437 · tm2425266-1_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
September 28, 2023 Filed Sep 29, 2023 21:01 UTC	Altimmune, Inc. ALT · Entity 5349	GrantStock Options (option to buy) · Derivative	26,100	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001104659-23-105395 · tm2327241-5_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock, par value $0.0001 · 26,100 shares Expires 2033-09-28 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
August 14, 2023 Filed Aug 15, 2023 22:02 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,241	$138.16	$171,454.70	Disclosure SEC source: 0001765581-23-000092 · edgardoc.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,868 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.78 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 11, 2023 Filed Aug 15, 2023 22:02 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	3,075	$0.00	$0.00	Disclosure SEC source: 0001765581-23-000092 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,109 F1 · kind: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Read SEC document
March 23, 2023 Filed Mar 27, 2023 20:17 UTC	Altimmune, Inc. ALT · Entity 5349	GrantStock Options (option to buy) · Derivative	47,000	$0.00 Strike: $4.19	$0.00	Disclosure SEC source: 0001104659-23-037128 · tm2310588-4_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock, par value $0.0001 · 47,000 shares Expires 2033-03-23 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in 36 substantially equal monthly installments following March 23, 2023, subject to the reporting person's continued service through the applicable vesting Read SEC document
August 08, 2022 Filed Aug 9, 2022 22:44 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,089	$152.32	$165,879.64	Disclosure SEC source: 0001765581-22-000100 · edgardoc.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,034 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 05, 2022 Filed Aug 9, 2022 22:44 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	2,561	$0.00	$0.00	Disclosure SEC source: 0001765581-22-000100 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,123 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:16 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016485 · wf-form4_165463657846481.xml · derivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,059 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 4, 2021. F3 · derivative.exercise_date: The restricted stock units vested on June 4, 2022. F3 · derivative.expiration_date: The restricted stock units vested on June 4, 2022. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:16 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016485 · wf-form4_165463657846481.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,069 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:46 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	9,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-016009 · wf-form4_165418835785568.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Stock · 9,474 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
May 19, 2022 Filed May 23, 2022 20:56 UTC	Axcella Health Inc. AXLA · Entity 116059	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.70	$0.00	Disclosure SEC source: 0001104659-22-063913 · tm2216627-8_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document
May 12, 2022 Filed May 13, 2022 16:26 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.24	$0.00	Disclosure SEC source: 0001179110-22-003004 · edgar.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:40 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,306	$147.96	$193,235.76	Disclosure SEC source: 0001765581-21-000110 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,562 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
July 29, 2021 Filed Aug 2, 2021 22:28 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	2,246	$0.00	$0.00	Disclosure SEC source: 0001765581-21-000085 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,868 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022. Read SEC document
June 04, 2021 Filed Jun 9, 2021 00:04 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	7,059	Not disclosed	Not disclosed	Disclosure SEC source: 0001593968-21-001573 · primary_01.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059 Underlying: Common Stock · 7,059 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:03 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	8,303	$11.64	$96,646.92	Disclosure SEC source: 0001593968-21-001522 · primary_01.xml · derivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,303 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 1, 2020. F3 · derivative.exercise_date: The restricted stock units vested on June 1, 2021. F3 · derivative.expiration_date: The restricted stock units vested on June 1, 2021. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:03 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	8,303	$11.64	$96,646.92	Disclosure SEC source: 0001593968-21-001522 · primary_01.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,010 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
May 20, 2021 Filed May 24, 2021 21:19 UTC	Axcella Health Inc. AXLA · Entity 116059	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.24	$0.00	Disclosure SEC source: 0001104659-21-071353 · tm2116997-8_4seq1.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document
May 12, 2021 Filed May 13, 2021 20:35 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $23.25	$0.00	Disclosure SEC source: 0001179110-21-005315 · edgar.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:42 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,500	$0.00 Strike: $81.76	$0.00	Disclosure SEC source: 0001765581-20-000109 · edgardoc.xml · derivative · entry 6 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,500 shares Expires 2023-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This non-qualified stock option was granted on August 8, 2013. The ordinary shares subject to this option award vested over 1 year in 12 equal monthly installments and were fully vested as of September 1, 2014. Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:42 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	8,000	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-20-000109 · edgardoc.xml · derivative · entry 5 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,000 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This non-qualified stock option was granted on August 9, 2012. The ordinary shares subject to this option award vested over 1 year in 12 equal monthly installments and were fully vested as of August 9, 2013. Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:42 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	8,000	$152.00	$1,216,000.00	Disclosure SEC source: 0001765581-20-000109 · edgardoc.xml · nonDerivative · entry 4 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,622 Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:42 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	8,000	$46.83	$374,640.00	Disclosure SEC source: 0001765581-20-000109 · edgardoc.xml · nonDerivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:42 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	4,500	$156.00	$702,000.00	Disclosure SEC source: 0001765581-20-000109 · edgardoc.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,622 Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:42 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	4,500	$81.76	$367,920.00	Disclosure SEC source: 0001765581-20-000109 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:14 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	2,200	$0.00	$0.00	Disclosure SEC source: 0001593968-20-002068 · primary_01.xml · derivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,200 shares Expires 2020-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on October 15, 2019. F3 · derivative.exercise_date: The restricted stock units vested on October 15, 2020. F3 · derivative.expiration_date: The restricted stock units vested on October 15, 2020. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:14 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	2,200	$10.36	$22,792.00	Disclosure SEC source: 0001593968-20-002068 · primary_01.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,707 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
August 07, 2020 Filed Aug 10, 2020 20:54 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	931	$125.87	$117,185.71	Disclosure SEC source: 0001765581-20-000083 · edgardoc.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,622 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:54 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	6,765	$0.00 Strike: $127.07	$0.00	Disclosure SEC source: 0001765581-20-000083 · edgardoc.xml · derivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Underlying: Ordinary Shares · 6,765 shares Expires 2030-08-05 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021. Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:54 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	2,705	$0.00	$0.00	Disclosure SEC source: 0001765581-20-000083 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,553 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021. Read SEC document
June 01, 2020 Filed Jun 2, 2020 22:21 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRight to Buy Restricted Stock Unit (RSU) · Derivative	8,303	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-008846 · wf-form4_159113648552749.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,303 Underlying: Common Stock · 8,303 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
May 28, 2020 Filed May 29, 2020 19:52 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	6,000	$0.00	$0.00	Disclosure SEC source: 0001628280-20-008626 · wf-form4_159078195594533.xml · derivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2020-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on May 28, 2019. F3 · derivative.exercise_date: The restricted stock units vested on May 28, 2020. F3 · derivative.expiration_date: The restricted stock units vested on May 28, 2020. Read SEC document
May 28, 2020 Filed May 29, 2020 19:52 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	6,000	$10.99	$65,940.00	Disclosure SEC source: 0001628280-20-008626 · wf-form4_159078195594533.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,507 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
May 21, 2020 Filed May 26, 2020 19:24 UTC	Rubius Therapeutics, Inc. RUBY · Entity 116417	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $6.22	$0.00	Disclosure SEC source: 0001179110-20-006604 · edgar.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.